VIBERZI Drug Patent Profile

When do Viberzi patents expire, and what generic alternatives are available?

Viberzi is a drug marketed by Abbvie and is included in one NDA. There are fourteen patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and fifty-three patent family members in forty countries.

The generic ingredient in VIBERZI is eluxadoline. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the eluxadoline profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Viberzi

A generic version of VIBERZI was approved as eluxadoline by AUROBINDO PHARMA on June 2^nd, 2026.

Summary for VIBERZI

International Patents:	153
US Patents:	14
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	36
Clinical Trials:	2
Patent Applications:	238
Drug Prices:	Drug price information for VIBERZI
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VIBERZI
What excipients (inactive ingredients) are in VIBERZI?	VIBERZI excipients list
DailyMed Link:	VIBERZI at DailyMed

See drug prices for VIBERZI

Recent Clinical Trials for VIBERZI

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Temple University	Phase 2/Phase 3
University of North Carolina, Chapel Hill	Phase 2
Allergan	Phase 2

See all VIBERZI clinical trials

Pharmacology for VIBERZI

Drug Class	mu-Opioid Receptor Agonist
Mechanism of Action	Opioid mu-Receptor Agonists

Paragraph IV (Patent) Challenges for VIBERZI

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VIBERZI	Tablets	eluxadoline	75 mg and 100 mg	206940	6	2019-05-28

US Patents and Regulatory Information for VIBERZI

VIBERZI is protected by fifteen US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	VIBERZI	eluxadoline	TABLET;ORAL	206940-002	May 27, 2015	AB	RX	Yes	Yes			Y
Abbvie	VIBERZI	eluxadoline	TABLET;ORAL	206940-001	May 27, 2015	AB	RX	Yes	No			Y	Y
Abbvie	VIBERZI	eluxadoline	TABLET;ORAL	206940-002	May 27, 2015	AB	RX	Yes	Yes				Y
Abbvie	VIBERZI	eluxadoline	TABLET;ORAL	206940-002	May 27, 2015	AB	RX	Yes	Yes			Y	Y
Abbvie	VIBERZI	eluxadoline	TABLET;ORAL	206940-001	May 27, 2015	AB	RX	Yes	No			Y
Abbvie	VIBERZI	eluxadoline	TABLET;ORAL	206940-001	May 27, 2015	AB	RX	Yes	No			Y

Expired US Patents for VIBERZI

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	VIBERZI	eluxadoline	TABLET;ORAL	206940-002	May 27, 2015
Abbvie	VIBERZI	eluxadoline	TABLET;ORAL	206940-002	May 27, 2015
Abbvie	VIBERZI	eluxadoline	TABLET;ORAL	206940-002	May 27, 2015
Abbvie	VIBERZI	eluxadoline	TABLET;ORAL	206940-001	May 27, 2015
Abbvie	VIBERZI	eluxadoline	TABLET;ORAL	206940-001	May 27, 2015
Abbvie	VIBERZI	eluxadoline	TABLET;ORAL	206940-001	May 27, 2015

EU/EMA Drug Approvals for VIBERZI

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Allergan Pharmaceuticals International Limited	Truberzi	eluxadoline	EMEA/H/C/004098Truberzi is indicated in adults for the treatment of irritable bowel syndrome with diarrhoea (IBS D).	Withdrawn	no	no	no	2016-09-19

International Patents for VIBERZI

When does loss-of-exclusivity occur for VIBERZI?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

Hong Kong

Hungary

Israel

Japan

Poland

Portugal

Slovenia

South Korea

Spain

Taiwan

Turkey

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VIBERZI around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2014241076
Brazil	112015022753
Canada	2906472
Canada	3254178
China	105228629
China	110917159

Supplementary Protection Certificates for VIBERZI

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1725537	CA 2017 00008	Denmark		PRODUCT NAME: ELUXADOLIN ELLER EN FARMACEUTISK ACCEPTABEL ENANTIOMER, DIASTEREOMER, RACEMAT ELLER SALT DERAF; REG. NO/DATE: EU/1/16/1126 20160921
1725537	300865	Netherlands		PRODUCT NAME: ELUXADOLINE OF EEN FARMACEUTISCH AANVAARDBAAR ENANTIOMEER,DIASTEREOMEER, RACEMAAT OF ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/16/1126 20160921
1725537	PA2017005	Lithuania		PRODUCT NAME: ELUKSADOLINAS ARBA JO FARMACINIU POZIURIU PRIIMTINAS ENANTIOMERAS, DIASTEREOMERAS, RACEMATAS ARBA DRUSKA; REGISTRATION NO/DATE: EU/1/16/1126 20160919
1725537	122017000009	Germany		PRODUCT NAME: ELUXADOLIN ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON; REGISTRATION NO/DATE: EU/1/16/1126 20160919
2176234	122017000010	Germany		PRODUCT NAME: ELUXADOLIN; REGISTRATION NO/DATE: EU/1/16/1126 20160919
1725537	1790007-7	Sweden		PRODUCT NAME: ELUXADOLINE OR A PHARMACEUTICALLY ACCEPTABLE ENANTIOMER, DIASTEREOMER, RACEMATE OR SALT THEREOF; REG. NO/DATE: EU/1/16/1126 20160921

Viberzi (Eluxadoline) Market Dynamics and Financial Trajectory: Exclusivity, Patent/Generic Timelines, Competitor Impact, and Revenue Risk

Last updated: May 28, 2026

Viberzi (eluxadoline) generates revenue tied to uptake for IBS-D (irritable bowel syndrome with diarrhea), payer access, and persistence. Its commercial trajectory is constrained by limited long-term exclusivity duration and a crowded IBS-D competitive field that pressures net price through formulary placement. Key market risks are generic entry timing, label-for-label substitution, and the ability to defend lifecycle IP around formulations, dosing regimens, and method-of-use.

What patents protect Viberzi (eluxadoline) and how strong is the patent estate?

Eluxadoline is a small molecule for IBS-D. Patent coverage for Viberzi typically spans compound claims, formulation and solid-state claims, and method-of-use related to treating IBS-D subpopulations (for example, diarrhea-predominant IBS). Market impact hinges on how much of Orange Book coverage is expiring first and what claims remain enforceable around the commercial product form and dosing regimen.

Which entities hold Viberzi’s US patent rights?

Patent protection is split across assignees that may include the original NDA holder and related corporate owners through acquisition or reorganization. The practical diligence point for market dynamics is the remaining life of the most relevant Orange Book-listed patents that map to the commercial drug.

What is covered by the typical Viberzi IP buckets?

• Active ingredient (compound) IP: generally earliest expiring.
• Formulation and dosage form IP: can extend exclusivity by covering specific tablet composition, solid-state attributes, or manufacturing-related parameters.
• Method-of-use IP: can delay generics if a generic product would infringe use claims tied to dosing or patient subsets.

How does patent strength translate into revenue exposure?

Revenue risk increases when the Orange Book “last expiring” patent weakens or if infringement defenses are limited to narrow claims. For a branded CNS-gastrointestinal product like Viberzi, lifecycle claims can still protect revenue until the last enforceable listed patent expires or a successful challenge creates a faster generic path.

When does Viberzi lose exclusivity and what is the generic entry risk?

Generic entry risk is driven by:

1. Orange Book patent expiration and exclusivity (if any) tied to the NDA, and
2. whether an ANDA holder files a Paragraph IV (if patents are listed and challengable), and
3. the time needed for FDA approval and launch readiness.

Key exclusivity and expiration timeline mechanics

For branded small molecules, exclusivity often ends with:

• Patent expiration of the last listed Orange Book patent.
• Any regulatory exclusivities (NCE/other) that may have a separate end date.

The market dynamic is that revenue often declines before formal loss of exclusivity due to payer contracting, brand-unfriendly price actions, and stocking behavior by wholesalers.

What Paragraph IV challenges drive Viberzi launch timing?

Paragraph IV challenges can cause:

• A potential 180-day exclusivity for the first filer,
• Automatic stays if required by law, and
• Settlement agreements that shift generic launch dates.

Revenue exposure to generic competition depends on whether a generic launch is “at-risk” or delayed by litigation and settlement.

What is the Orange Book status of Viberzi (eluxadoline) and which patents are listed?

The practical market diligence step is to map:

• US patent numbers listed in the Orange Book for Viberzi’s NDA,
• Expiration dates for each listed patent,
• Whether each patent covers drug substance, drug product (formulation), or use, and
• Which patents have already expired versus which remain active.

This determines the credible generic entry window and the likely pace of price erosion.

How to interpret Orange Book listings for market models

• If most listed patents are expiring soon, the revenue curve steepens.
• If formulation or use patents remain, generic entry can be delayed or blocked for specific labeling claims.

What formulations and dosing regimens are protected by Viberzi IP?

For a marketed IBS-D therapy, protection often includes:

• Tablet composition and excipient systems,
• Dose strength-specific composition (if separate strengths have separate claims),
• Method-of-use tied to IBS-D diagnosis criteria and diarrhea frequency endpoints.

Why formulation IP matters for market dynamics

Even if a generic can match API and strength, formulation and manufacturing-linked claims can require design-arounds. If design-arounds raise cost or reduce bioavailability equivalence, payers may delay switching.

Why method-of-use IP matters for substitution and launch labels

If use claims are enforceable, an FDA-approved generic may be constrained by labeling (or may be blocked by litigation), slowing uptake.

What generic entry risks exist for Viberzi and how quickly can switching happen?

Switching speed is influenced by:

• formulary incentives (preferred status for alternatives),
• whether competitors are therapeutically substitutable for IBS-D,
• pharmacist and physician comfort with switching small molecules for GI indications,
• and the magnitude of net price discounting required to displace the branded product.

Real-world barriers that slow generic uptake

• Clinical familiarity with branded dosing
• Patient adherence behavior (GI side effect profiles can make prescribers reluctant to switch)
• Payer step therapy that keeps branded therapy in place until plan renewals

What drives rapid price erosion once a generic launches

• Multiple ANDA approvals
• Availability of multiple generic SKUs and strong wholesale distribution terms
• Aggressive contracting by PBMs once substitution is permitted

How does Viberzi compare with other IBS-D therapies in market and revenue pressure?

Viberzi faces substitution pressure from other IBS-D marketed options and from therapies that address overlapping symptoms through different mechanisms.

Competitive dimension 1: Mechanism and positioning for IBS-D

Eluxadoline is positioned for IBS-D symptom control. Competitors can take market share when they:

• show stronger symptom response,
• offer better tolerability,
• or achieve superior formulary access.

Competitive dimension 2: Payer access and net price dynamics

Branded IBS drugs often lose gross-to-net share through rebates and formulary exclusivity expirations. Revenue trajectory depends on how effectively the manufacturer defends:

• preferred tier placement,
• prior authorization criteria,
• and step edits.

Competitive dimension 3: Safety and labeling constraints

GI and opioid-receptor related safety considerations affect prescriber comfort and patient selection. Any label restrictions or contraindication-driven use limitations can cap addressable market growth and increase churn risk when alternatives are easier to use.

What patent litigation affects Viberzi and does it change launch calendars?

Patent litigation affects:

• whether generics can launch at risk,
• whether exclusivity periods are protected via stays,
• and whether settlements shift launch dates.

What outcomes matter most for revenue forecasting

• Win by brand: delays generic entry and supports price.
• Narrow ruling: enables generic entry on a date but with label restrictions or delayed product-specific launch.
• Settlement with delayed launch: preserves brand revenue for the settlement period.
• Settlement with early launch: can force more rapid price erosion.

How to model revenue impact from litigation posture

Revenue curves respond to credible calendar dates. A litigation-driven extension of exclusivity can sustain net price and volume longer than expected from patent expiration alone.

What FDA regulatory pathway and status drive Viberzi’s commercial trajectory?

Viberzi is approved for IBS-D under the US NDA approval framework. Market dynamics depend on:

• whether generic applications are filed under ANDA,
• how the label supports substitution,
• and whether REMS-like restrictions or safety updates change prescriber behavior.

Post-marketing changes that affect adoption

Safety communications and label updates can reduce addressable patient pools, altering prescription trends. FDA communications that expand or restrict contraindications can shift prescribing patterns to competing agents.

Which commercial metrics most explain Viberzi’s financial trajectory?

Viberzi’s financial trajectory is typically explained by:

• prescription volume trend (new starts and persistence),
• net pricing (rebates, wholesaler terms, PBM contracting),
• channel inventory and stocking cycles, and
• formulary placement changes driven by PBM contracting.

Revenue decomposition framework for branded IBS products

• Gross sales are driven by scripts and average selling price.
• Net revenue is impacted by rebates and chargebacks.
• Post-generic threats push manufacturers toward higher rebates to retain tier placement, compressing net margin.

How much revenue exposure does Viberzi face from generic substitution?

Revenue exposure is greatest when:

• the last listed Orange Book patent is near expiry,
• credible Paragraph IV challenges have been filed,
• litigation does not create stays,
• and competitors are already on formularies.

Once substitution is enabled, brand revenue decline often accelerates due to rapid switching and stronger PBM incentives for generics.

Revenue impact levers

• Brand share loss rate after generic entry
• Net price decline (rebate growth and wholesaler price pressure)
• Offset strategy via patient support programs or contracting rebalancing

Key Takeaways

• Viberzi’s revenue trajectory is governed by payer access, IBS-D competitive substitution, and the timing of Orange Book expirations and any Paragraph IV-driven generic pathways.
• Patent strength matters most when formulation or method-of-use claims remain enforceable near the end of listed patent life, slowing or shaping generic launch and labeling.
• Generic entry risk is modeled through Orange Book listed patents, litigation posture, and settlement calendars, which together determine how quickly net price erodes.
• Commercial downside accelerates as credible generic entry windows approach, even before formal loss of exclusivity, driven by payer contracting and anticipatory substitution behavior.

FAQs

1. How do Orange Book “drug product” patents for Viberzi affect ANDA launch timing?
2. What role do method-of-use patents play in limiting Viberzi generic labeling or substitution?
3. How do Paragraph IV settlements typically change the generic launch calendar for branded GI drugs like Viberzi?
4. Which payer formulary and rebate mechanisms drive Viberzi net sales decline ahead of generic entry?
5. How does competing IBS-D efficacy and tolerability influence Viberzi prescription persistence?

References (APA)

1. FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. FDA. (n.d.). ANDA and Paragraph IV certification guidance and information. U.S. Food and Drug Administration.

DrugChatter Q&A for VIBERZI

Viberzi generic availability?
Viberzi medication generic?
Why is viberzi so expensive?
How much does viberzi cost?
Viberzi cost with insurance?